These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35326662)

  • 21. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Kus T; Aktas G; Sevinc A; Kalender ME; Yilmaz M; Kul S; Oztuzcu S; Oktay C; Camci C
    Onco Targets Ther; 2015; 8():3749-56. PubMed ID: 26719702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
    Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
    Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of metabolic parameters measured by
    Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
    J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Gao XC; Wei CH; Zhang RG; Cai Q; He Y; Tong F; Dong JH; Wu G; Dong XR
    Oncol Lett; 2020 Oct; 20(4):61. PubMed ID: 32863894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Value of
    Werner RA; Schmid JS; Higuchi T; Javadi MS; Rowe SP; Märkl B; Aulmann C; Fassnacht M; Kroiss M; Reiners C; Buck AK; Kreissl MC; Lapa C
    J Nucl Med; 2018 May; 59(5):756-761. PubMed ID: 29025983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.
    van Gool MH; Aukema TS; Hartemink KJ; Valdés Olmos RA; van Tinteren H; Klomp HM
    World J Radiol; 2014 Jul; 6(7):392-8. PubMed ID: 25071879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.
    Seifert R; Küper A; Tewes M; Heuschmid M; Welt A; Fendler WP; Herrmann K; Decker T
    Oncol Res Treat; 2021; 44(7-8):400-407. PubMed ID: 34102639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
    Ueno D; Yao M; Tateishi U; Minamimoto R; Makiyama K; Hayashi N; Sano F; Murakami T; Kishida T; Miura T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2012 May; 12():162. PubMed ID: 22551397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
    Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
    PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
    Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
    Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between EGFR mutation status and F
    Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
    Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
    Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
    [No Abstract]   [Full Text] [Related]  

  • 39.
    Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
    Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
    [No Abstract]   [Full Text] [Related]  

  • 40. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
    Sunaga N; Oriuchi N; Kaira K; Yanagitani N; Tomizawa Y; Hisada T; Ishizuka T; Endo K; Mori M
    Lung Cancer; 2008 Feb; 59(2):203-10. PubMed ID: 17913282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.